Trial Profile
A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2022
Price :
$35
*
At a glance
- Drugs Ad26 EBOV vaccine (Primary) ; Modified Vaccinia Ankara Bavarian Nordic Ebola Marburg vaccine (Primary)
- Indications Ebola virus infections
- Focus Adverse reactions
- Sponsors Janssen; Janssen Vaccines and Prevention
- 01 Jan 2022 Results published in the PLOS Medicine
- 19 Mar 2019 Status changed from active, no longer recruiting to completed.
- 17 Aug 2018 Planned primary completion date changed from 21 Jan 2019 to 7 Mar 2019.